Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CXCR5-modified EGFR CAR-T in Advanced NSCLC
NCT04153799Phase 1Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2019
- Primary completion
- Dec 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CXCR5-modified EGFR chimeric antigen receptor T cells in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoints: Safety by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 at 52 weeks and Objective Response Rate at 52 weeks. Status: unknown.
02
Drugs
CXCR5-modified EGFR chimeric antigen receptor T cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04153799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153799.